Molecular Cause Found for Rare Autoimmune Disorders
By LabMedica International staff writers Posted on 01 Jan 2019 |
Image: The Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer (Photo courtesy of Thermo Fisher Scientific).
It is estimated that more than 20 million Americans suffer from autoimmune disorders. They include rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, lupus, type 1 diabetes, and dozens of others.
There are very few safe and effective treatments for such disorders, largely because so little is understood about how they arise and are sustained. In several autoimmune disorders, including Singleton-Merten syndrome (SMS), Aicardi-Goutières syndrome, familial chilblain lupus, proteasome associated autoinflammatory syndromes and many others involve improper stimulation of interferon.
Scientists at the Scripps Research Institute (Jupiter, FL, USA) have found a molecular cause of a group of rare autoimmune disorders in which the immune system attacks the body's own healthy cells. Interferon is a key component of the frontline defense against pathogens. Interferon earned its name because it literally interferes with virus' ability to make copies of themselves. The immune system relies on a gene called retinoic acid inducible gene-I, (RIG-I) to signal for the release of interferon whenever certain viral markers are encountered. RIG-I has to determine if the markers are of foreign origin or are from its own body.
Peptides were identified using tandem mass spectrometry (MS/MS) with the Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer. The team used hydrogen-deuterium exchange mass spectrometry (HDX-MS), which enables scientists to analyze the structures and dynamics of just such proteins. For the study, they applied HDX-MS to normal and mutant RIG-I, and essentially solved the mystery of how these mutations cause a failure of discrimination between self and viral RNA.
Most viruses have genes made of ribonucleic acid, or RNA, a close chemical cousin of DNA. RIG-I works as an early-warning detector of viral RNA, capable of triggering a broad antiviral immune response, including interferon release. The scientists showed that mutations in RIG-I cause the sensor protein to activate even when it encounters non-viral, "self" RNA. Jie Zheng, PhD, a postdoctoral associate and the first and co-corresponding author of the study, said, “This dysregulated molecular mechanism of RIG-I mediated RNA proofreading that we identified may help us understand and treat SMS and other autoimmune disorders.” The study was published on December 18, 2018, in the journal Nature Communications.
Related Links:
Scripps Research Institute
There are very few safe and effective treatments for such disorders, largely because so little is understood about how they arise and are sustained. In several autoimmune disorders, including Singleton-Merten syndrome (SMS), Aicardi-Goutières syndrome, familial chilblain lupus, proteasome associated autoinflammatory syndromes and many others involve improper stimulation of interferon.
Scientists at the Scripps Research Institute (Jupiter, FL, USA) have found a molecular cause of a group of rare autoimmune disorders in which the immune system attacks the body's own healthy cells. Interferon is a key component of the frontline defense against pathogens. Interferon earned its name because it literally interferes with virus' ability to make copies of themselves. The immune system relies on a gene called retinoic acid inducible gene-I, (RIG-I) to signal for the release of interferon whenever certain viral markers are encountered. RIG-I has to determine if the markers are of foreign origin or are from its own body.
Peptides were identified using tandem mass spectrometry (MS/MS) with the Q Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer. The team used hydrogen-deuterium exchange mass spectrometry (HDX-MS), which enables scientists to analyze the structures and dynamics of just such proteins. For the study, they applied HDX-MS to normal and mutant RIG-I, and essentially solved the mystery of how these mutations cause a failure of discrimination between self and viral RNA.
Most viruses have genes made of ribonucleic acid, or RNA, a close chemical cousin of DNA. RIG-I works as an early-warning detector of viral RNA, capable of triggering a broad antiviral immune response, including interferon release. The scientists showed that mutations in RIG-I cause the sensor protein to activate even when it encounters non-viral, "self" RNA. Jie Zheng, PhD, a postdoctoral associate and the first and co-corresponding author of the study, said, “This dysregulated molecular mechanism of RIG-I mediated RNA proofreading that we identified may help us understand and treat SMS and other autoimmune disorders.” The study was published on December 18, 2018, in the journal Nature Communications.
Related Links:
Scripps Research Institute
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders